Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 85OTHER 47NETWORK 11NIH 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Neoplasms 1

Interventions

Cisplatin 49Capecitabine 41apatinib 34Gemcitabine 33Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Surgical Procedures, Operative 17Nivolumab 17pembrolizumab 16Exercise 16Metformin 15camrelizumab 14S 1 (combination) 14Radiation 14Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11toripalimab 10Vinorelbine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Ramucirumab × Clear all
NCT02999295 2019-08-21

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

National Cancer Center, Japan

Phase 1/2 Completed
46 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡